{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:04:17Z","timestamp":1792116257703,"version":"4.4.0"},"reference-count":41,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The B-cell lymphoma protein 2 (Bcl-2) inhibitor venetoclax remains the sole apoptosis-inducing agent approved for combination therapy in older patients with acute myeloid leukemia (AML). However, its clinical efficacy is frequently constrained by the emergence of drug resistance, which involves the overexpression or induction of the myeloid cell leukemia 1 (Mcl-1) and B-cell lymphoma-extra large (Bcl-xL) proteins. To address this challenge, we developed a novel strategy to enhance venetoclax activity and overcome resistance by producing NOXA through the conjugation of dihydroartemisinin (DHA) to venetoclax using a chemical synthesis approach. The produced conjugate, A1, retained potent Bcl-2 inhibitory activity and significantly enhanced NOXA production by promoting interactions between the DHA-derived endoperoxide bridge and heme. Mechanistically, A1 effectively overcomes resistance caused by Mcl-1 and Bcl-xL protein through NOXA-mediated Mcl-1 and cyclin D1 protein degradation, respectively. Optimization of the linker design of A1 yielded polyethylene glycol (PEG)-linked conjugates with increased in vivo efficacy. This study introduced a new generation of venetoclax-based compounds with dual functionality, specifically enhanced NOXA production and robust degradation of antiapoptotic and cell cycle\u2013regulating proteins. Furthermore, we uncovered a promising therapeutic strategy to overcome drug resistance in venetoclax-based AML treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025015806","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T20:02:41Z","timestamp":1755028961000},"page":"5473-5488","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Overcoming venetoclax resistance through heme-mediated NOXA\/cyclin D1\/Mcl-1 axis with a novel artemisinin conjugate"],"prefix":"10.1182","volume":"9","author":[{"given":"Jingyi","family":"Zhang","sequence":"first","affiliation":[{"name":"1Department of Pharmacology, Liaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"2Department of Medicinal Chemistry, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Liu","sequence":"additional","affiliation":[{"name":"3Department of Hematology, Northern Theater General Hospital, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenglin","family":"Luan","sequence":"additional","affiliation":[{"name":"2Department of Medicinal Chemistry, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiqiang","family":"Qu","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, Liaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi","family":"Wu","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, Liaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Kuang","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, Liaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Gong","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, Liaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Bao","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, Liaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuetong","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, Liaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-0369","authenticated-orcid":false,"given":"Xiaojing","family":"Yan","sequence":"additional","affiliation":[{"name":"4Department of Hematology, The First Affiliated Hospital of China Medical University, Shenyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Waxman","sequence":"additional","affiliation":[{"name":"5Division of Hematology\/Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-5781","authenticated-orcid":false,"given":"Linxiang","family":"Zhao","sequence":"additional","affiliation":[{"name":"2Department of Medicinal Chemistry, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkui","family":"Jing","sequence":"additional","affiliation":[{"name":"1Department of Pharmacology, Liaoning Key Laboratory of Targeting Drugs for Hematological Malignancies, Shenyang Pharmaceutical University, Shenyang, People's Republic of China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"3","key":"2025111014170783700_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2174\/156800908784293640","article-title":"Deregulation of the mitochondrial apoptotic machinery and development of molecular targeted drugs in acute myeloid leukemia","volume":"8","author":"Del Poeta","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"2025111014170783700_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/cdd.2017.161","article-title":"The BCL-2 arbiters of apoptosis and their growing role as cancer targets","volume":"25","author":"Adams","year":"2018","journal-title":"Cell Death Differ"},{"issue":"6059","key":"2025111014170783700_bib3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1126\/science.1206727","article-title":"Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy","volume":"334","author":"Ni Chonghaile","year":"2011","journal-title":"Science"},{"issue":"1","key":"2025111014170783700_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat Rev Cancer"},{"key":"2025111014170783700_bib5","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.12688\/f1000research.9629.1","article-title":"Mitochondrial apoptosis and BH3 mimetics","volume":"5","author":"Dai","year":"2016","journal-title":"F1000Res"},{"issue":"16","key":"2025111014170783700_bib6","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1158\/1078-0432.CCR-16-0955","article-title":"Venetoclax in patients with previously treated chronic lymphocytic leukemia","volume":"23","author":"Roberts","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025111014170783700_bib7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/MOH.0000000000000485","article-title":"Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?","volume":"26","author":"Pollyea","year":"2019","journal-title":"Curr Opin Hematol"},{"issue":"24","key":"2025111014170783700_bib8","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2025111014170783700_bib9","doi-asserted-by":"crossref","first-page":"5802","DOI":"10.3390\/ijms24065802","article-title":"Landscape of BCL2 resistance mutations in a real-world cohort of patients with relapsed\/refractory chronic lymphocytic leukemia treated with venetoclax","volume":"24","author":"Kotmayer","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2025111014170783700_bib10","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1182\/blood.2022016090","article-title":"Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemia","volume":"141","author":"Moujalled","year":"2023","journal-title":"Blood"},{"issue":"20","key":"2025111014170783700_bib11","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1182\/blood.2020010167","article-title":"Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias","volume":"137","author":"Thijssen","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2025111014170783700_bib12","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s10585-022-10189-0","article-title":"Resistance to targeted therapies in acute myeloid leukemia","volume":"40","author":"Mecklenbrauck","year":"2023","journal-title":"Clin Exp Metastasis"},{"issue":"21","key":"2025111014170783700_bib13","doi-asserted-by":"crossref","first-page":"4844","DOI":"10.1158\/1078-0432.CCR-24-0028","article-title":"A phase 1 first-in-human study of the MCL-1 inhibitor AZD5991 in patients with relapsed\/refractory hematologic malignancies","volume":"30","author":"Desai","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2025111014170783700_bib14","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2025111014170783700_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41418-019-0486-3","article-title":"Saga of Mcl-1: regulation from transcription to degradation","volume":"27","author":"Senichkin","year":"2020","journal-title":"Cell Death Differ"},{"issue":"22","key":"2025111014170783700_bib16","doi-asserted-by":"crossref","first-page":"16223","DOI":"10.1074\/jbc.M611186200","article-title":"Functional linkage between NOXA and Bim in mitochondrial apoptotic events","volume":"282","author":"Han","year":"2007","journal-title":"J Biol Chem"},{"issue":"8","key":"2025111014170783700_bib17","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/14728222.2017.1349754","article-title":"Exploiting the pro-apoptotic function of NOXA as a therapeutic modality in cancer","volume":"21","author":"Guikema","year":"2017","journal-title":"Expert Opin Ther Targets"},{"issue":"4","key":"2025111014170783700_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41419-022-04810-z","article-title":"Artesunate improves venetoclax plus cytarabine AML cell targeting by regulating the Noxa\/Bim\/Mcl-1\/p-Chk1 axis","volume":"13","author":"Zhang","year":"2022","journal-title":"Cell Death Dis"},{"issue":"8","key":"2025111014170783700_bib19","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.18632\/oncotarget.3336","article-title":"Dihydroartemisinin and its derivative induce apoptosis in acute myeloid leukemia through Noxa-mediated pathway requiring iron and endoperoxide moiety","volume":"6","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"2025111014170783700_bib20","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1124\/mol.110.068528","article-title":"Bcl-xL is a dominant antiapoptotic protein that inhibits homoharringtonine-induced apoptosis in leukemia cells","volume":"79","author":"Yin","year":"2011","journal-title":"Mol Pharmacol"},{"issue":"3","key":"2025111014170783700_bib21","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1158\/1535-7163.MCT-03-0266","article-title":"Boswellic acid acetate induces apoptosis through caspase-mediated pathways in myeloid leukemia cells","volume":"4","author":"Xia","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2025111014170783700_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41420-023-01317-0","article-title":"The GSK3\u03b2\/Mcl-1 axis is regulated by both FLT3-ITD and Axl and determines the apoptosis induction abilities of FLT3-ITD inhibitors","volume":"9","author":"Qiu","year":"2023","journal-title":"Cell Death Discov"},{"issue":"16","key":"2025111014170783700_bib23","doi-asserted-by":"crossref","first-page":"13925","DOI":"10.1021\/acs.jmedchem.4c00643","article-title":"Discovery of novel Mcl-1 inhibitors with a 3-substituted-1H-indole-1-yl moiety binding to the P1-P3 pockets to induce apoptosis in acute myeloid leukemia cells","volume":"67","author":"Deng","year":"2024","journal-title":"J Med Chem"},{"key":"2025111014170783700_bib24","doi-asserted-by":"crossref","first-page":"104455","DOI":"10.1016\/j.compbiomed.2021.104455","article-title":"Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy","volume":"134","author":"Krishna","year":"2021","journal-title":"Comput Biol Med"},{"issue":"3","key":"2025111014170783700_bib25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov"},{"issue":"3","key":"2025111014170783700_bib26","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3324\/haematol.2018.214882","article-title":"Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia","volume":"105","author":"Kuusanm\u00e4ki","year":"2020","journal-title":"Haematologica"},{"issue":"4","key":"2025111014170783700_bib27","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"issue":"2","key":"2025111014170783700_bib28","doi-asserted-by":"crossref","first-page":"380","DOI":"10.20517\/cdr.2021.125","article-title":"Venetoclax resistance: mechanistic insights and future strategies","volume":"5","author":"Ong","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"13","key":"2025111014170783700_bib29","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1182\/blood.2021011094","article-title":"Erythroid\/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia","volume":"141","author":"Kuusanm\u00e4ki","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2025111014170783700_bib30","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1074\/jbc.M110.144188","article-title":"The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials","volume":"286","author":"Mercer","year":"2011","journal-title":"J Biol Chem"},{"issue":"3","key":"2025111014170783700_bib31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","article-title":"A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma","volume":"31","author":"Fan","year":"2017","journal-title":"Cancer Cell"},{"key":"2025111014170783700_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.acr.2017.11.001","article-title":"Bcl-2 antiapoptotic family proteins and chemoresistance in cancer","volume":"137","author":"Maji","year":"2018","journal-title":"Adv Cancer Res"},{"issue":"1","key":"2025111014170783700_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"2025111014170783700_bib34","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-022-00283-0","article-title":"Progress in understanding the mechanisms of resistance to BCL-2 inhibitors","volume":"11","author":"Xu","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"25","key":"2025111014170783700_bib35","doi-asserted-by":"crossref","first-page":"17802","DOI":"10.1074\/jbc.M114.548172","article-title":"The carboxyl-terminal tail of Noxa protein regulates the stability of Noxa and Mcl-1","volume":"289","author":"Pang","year":"2014","journal-title":"J Biol Chem"},{"issue":"7","key":"2025111014170783700_bib36","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1182\/blood.V92.7.2495","article-title":"Mcl-1 expression in human neutrophils: regulation by cytokines and correlation with cell survival","volume":"92","author":"Moulding","year":"1998","journal-title":"Blood"},{"issue":"11","key":"2025111014170783700_bib37","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/cdd.2011.69","article-title":"Molecular analysis of neutrophil spontaneous apoptosis reveals a strong role for the pro-apoptotic BH3-only protein Noxa","volume":"18","author":"Kirschnek","year":"2011","journal-title":"Cell Death Differ"},{"issue":"1","key":"2025111014170783700_bib38","doi-asserted-by":"crossref","first-page":"e1013","DOI":"10.1038\/cddis.2013.552","article-title":"Discrepant NOXA (PMAIP1) transcript and NOXA protein levels: a potential Achilles' heel in mantle cell lymphoma","volume":"5","author":"Dengler","year":"2014","journal-title":"Cell Death Dis"},{"key":"2025111014170783700_bib39","doi-asserted-by":"crossref","first-page":"119029","DOI":"10.1016\/j.ica.2019.119029","article-title":"Artesunate activation by heme in an aqueous medium","volume":"496","author":"Heller","year":"2019","journal-title":"Inorg Chim Acta"},{"key":"2025111014170783700_bib40","doi-asserted-by":"crossref","first-page":"10111","DOI":"10.1038\/ncomms10111","article-title":"Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum","volume":"6","author":"Wang","year":"2015","journal-title":"Nat Commun"},{"issue":"5","key":"2025111014170783700_bib41","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cmet.2019.01.011","article-title":"Systematic dissection of the metabolic-apoptotic interface in AML reveals heme biosynthesis to be a regulator of drug sensitivity","volume":"29","author":"Lin","year":"2019","journal-title":"Cell Metab"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5473\/2418581\/blooda_adv-2025-015806-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5473\/2418581\/blooda_adv-2025-015806-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T19:17:16Z","timestamp":1762802236000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/21\/5473\/546656\/Overcoming-venetoclax-resistance-through-heme"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":41,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025015806","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,11]]},"published":{"date-parts":[[2025,10,30]]}}}